Tibet Cheezheng Tibetan Medicine Co., Ltd. (SHE:002287)
China · Delayed Price · Currency is CNY 21.05
+0.42 (2.04%)
May 29, 2026, 3:04 PM CST
SHE:002287 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,417 | 2,415 | 2,336 | 2,040 | 2,040 | 1,766 |
Other Revenue | 0.93 | 0.93 | 2.19 | 5.55 | 4.63 | 4.06 |
| 2,418 | 2,416 | 2,338 | 2,045 | 2,045 | 1,770 | |
Revenue Growth (YoY) | 1.78% | 3.34% | 14.32% | 0.02% | 15.49% | 19.22% |
Cost of Revenue | 401.32 | 410.66 | 419.55 | 324.7 | 325.52 | 269.7 |
Gross Profit | 2,017 | 2,005 | 1,918 | 1,720 | 1,719 | 1,501 |
Selling, General & Admin | 1,299 | 1,285 | 1,280 | 1,162 | 1,107 | 986.35 |
Research & Development | 84.51 | 81.03 | 66.73 | 58.63 | 55.09 | 70.82 |
Other Operating Expenses | 37.9 | 36.09 | 34.76 | 32.26 | 29.47 | 28.58 |
Operating Expenses | 1,420 | 1,401 | 1,382 | 1,253 | 1,192 | 1,084 |
Operating Income | 597.07 | 603.98 | 536.7 | 467.52 | 527.71 | 416.45 |
Interest Expense | -29.04 | -41.86 | -57.79 | -63.07 | -56.42 | -53.43 |
Interest & Investment Income | 8.96 | 8.5 | 4.19 | 41.92 | 16.96 | 340.33 |
Currency Exchange Gain (Loss) | -0.12 | -0.12 | -0.01 | -0.03 | -0.02 | -0.02 |
Other Non Operating Income (Expenses) | 9.94 | -1.04 | -0.02 | -1.16 | -3.56 | -2.46 |
EBT Excluding Unusual Items | 586.8 | 569.47 | 483.08 | 445.19 | 484.68 | 700.88 |
Impairment of Goodwill | - | - | - | - | - | -15.77 |
Gain (Loss) on Sale of Investments | 65.35 | 66.37 | 100.32 | 37.07 | -37.08 | 20.69 |
Gain (Loss) on Sale of Assets | 7.49 | 7.38 | - | 0.32 | 0 | -0.07 |
Asset Writedown | -0.67 | 0.06 | -0.58 | -0.3 | -1.22 | -0.35 |
Other Unusual Items | 100.88 | 96.57 | 63.43 | 162.14 | 72.82 | 82.54 |
Pretax Income | 759.85 | 739.84 | 646.24 | 644.41 | 519.2 | 787.91 |
Income Tax Expense | 93.51 | 92.37 | 64.87 | 65.24 | 49.56 | 77.09 |
Earnings From Continuing Operations | 666.34 | 647.47 | 581.37 | 579.18 | 469.64 | 710.83 |
Minority Interest in Earnings | 1.58 | 0.95 | 0.91 | 2.02 | 2.9 | 5.05 |
Net Income | 667.92 | 648.43 | 582.28 | 581.2 | 472.54 | 715.88 |
Net Income to Common | 667.92 | 648.43 | 582.28 | 581.2 | 472.54 | 715.88 |
Net Income Growth | 19.17% | 11.36% | 0.19% | 22.99% | -33.99% | 77.21% |
Shares Outstanding (Basic) | 552 | 544 | 530 | 530 | 530 | 529 |
Shares Outstanding (Diluted) | 552 | 544 | 530 | 530 | 530 | 529 |
Shares Change (YoY) | 4.12% | 2.50% | 0.03% | -0.05% | 0.21% | 0.12% |
EPS (Basic) | 1.21 | 1.19 | 1.10 | 1.10 | 0.89 | 1.35 |
EPS (Diluted) | 1.21 | 1.19 | 1.10 | 1.10 | 0.89 | 1.35 |
EPS Growth | 14.46% | 8.64% | 0.15% | 23.05% | -34.13% | 77.01% |
Free Cash Flow | 185.35 | 576.63 | 201.31 | 458.59 | 13.29 | 909.35 |
Free Cash Flow Per Share | 0.34 | 1.06 | 0.38 | 0.86 | 0.03 | 1.72 |
Dividend Per Share | 0.410 | 0.410 | 0.380 | 0.480 | 0.390 | 0.590 |
Dividend Growth | 7.90% | 7.90% | -20.83% | 23.08% | -33.90% | 73.53% |
Gross Margin | 83.40% | 83.00% | 82.06% | 84.12% | 84.08% | 84.77% |
Operating Margin | 24.69% | 25.00% | 22.96% | 22.86% | 25.81% | 23.52% |
Profit Margin | 27.62% | 26.84% | 24.91% | 28.42% | 23.11% | 40.43% |
Free Cash Flow Margin | 7.66% | 23.87% | 8.61% | 22.42% | 0.65% | 51.36% |
EBITDA | 734.42 | 739.51 | 664.94 | 552.96 | 604.13 | 476.77 |
EBITDA Margin | 30.37% | 30.61% | 28.44% | 27.04% | 29.54% | 26.93% |
D&A For EBITDA | 137.36 | 135.53 | 128.23 | 85.43 | 76.42 | 60.32 |
EBIT | 597.07 | 603.98 | 536.7 | 467.52 | 527.71 | 416.45 |
EBIT Margin | 24.69% | 25.00% | 22.96% | 22.86% | 25.81% | 23.52% |
Effective Tax Rate | 12.31% | 12.48% | 10.04% | 10.12% | 9.54% | 9.78% |
Revenue as Reported | 2,418 | 2,416 | 2,338 | 2,045 | 2,045 | 1,770 |